The Drug-Induced Respiratory Disease Website

I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)

I.a Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)

I.g QTc prolongation

II. Myocardial dysfunction - Heart failure

II.c Heart failure (biventricular, congestive)

VII. Cardiotoxicity

VII.a ‘Cardiotoxicity’

XVI. Hemorrhage - Bleeding - Hematoma(s)

XVI.e Alveolar hemorrhage (AH), diffuse AH (DAH)

XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.a Pneumonitis (ILD)

XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.m Subclinical pulmonary infiltrates/ILD

XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.u Transient pulmonary opacities/infiltrates (TAPO)

XXXIX. Rechallenge

XXXIX.a Rechallenge can lead to near-fatal or fatal relapse of AE/ILD

XXXIX. Rechallenge

XXXIX.e Rechallenge may not lead to relapse of the AE/ILD